While SGLT-2 inhibitors have a beneficial effect on the prevention and progression of heart failure based on data from trials such as EMPAREG-OUTCOME, CANVAS, or DECLARE-TIMI 58, GLP-1 receptor agonists were confirmed to have preventive effects on all-cause hospitalizations based on trials such as REWIND [13]. Here, GLP1R is linked to heart failure.